Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: An accelerated approach toward epitope-driven vaccine development

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 8, 2014, Pages 2366-2377

  Abdel Hady, Karim M ^a   Gutierrez, Andres H ^b   Terry, Frances ^c   Desrosiers, Joe ^b   De Groot, Anne S ^b,c   Azzazy, Hassan M E ^a  

^a The American University in Cairo   (Egypt)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c EpiVax Inc   (United States)

Author keywords

Genotype 4; Hepatitis C virus; Immune Epitope Database; Immunoinformatics; T cell epitopes; Vaccine; Validation

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 1; PROTEOME; VIRUS PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; EPITOPE MAPPING; HEPATITIS C VIRUS GENOTYPE 4; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; VALIDATION PROCESS; VIRUS GENOME; BIOLOGY; CENTRAL AFRICA; CLASSIFICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE EAST; PROCEDURES; VIROLOGY;

AFRICA, CENTRAL; COMPUTATIONAL BIOLOGY; CONSERVED SEQUENCE; EPITOPES, T-LYMPHOCYTE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MIDDLE EAST; PROTEOME; VIRAL PROTEINS;

EID: 84908439506     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29177     Document Type: Article

References (68)

1. World Health Organization. Hepatitis C fact sheet No164 [Internet]. [Updated 2013 Jul; Cited 2013 Nov 13]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.
2. World Health Organization. Hepatitis C [Internet]. 2002. [Cited 2013 Nov 13]. Available from: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index2.html.
3. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42:962-73; PMID:16149085; http://dx.doi.org/10.1002/hep.20819
4. Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, Esteban R, Abdo AA, Harrison SA, Ibrahim N, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54:1250-62; PMID:21316497; http://dx.doi.org/10.1016/j.jhep.2010.11.016
5. Centers for Disease Control and Prevention. Hepatitis C Information for Health Professionals [Internet]. 2011. [Cited 2013 Nov 13]. Available from: http://www.cdc.gov/hepatitis/HCV/index.htm
6. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5:453-63; PMID:17487147; http://dx.doi.org/10.1038/nrmicro1645
7. Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol 2008; 128:133-47; PMID:18514579; http://dx.doi.org/10.1016/j.clim.2008.03.525
8. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119:1745-54; PMID:19587449; http://dx.doi.org/10.1172/JCI39133
9. Lemon SM. Induction and evasion of innate antiviral responses by hepatitis C virus. J Biol Chem 2010; 285:22741-7; PMID:20457596; http://dx.doi.org/10.1074/jbc.R109.099556
10. Zeisel MB, Cosset FL, Baumert TF. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology 2008; 48:299-307; PMID:18508291; http://dx.doi.org/10.1002/hep.22307
11. Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 2011; 10:659-72; PMID:21604986; http://dx.doi.org/10.1586/erv.11.55
12. Yu CI, Chiang BL. A new insight into hepatitis C vaccine development. J Biomed Biotechnol 2010; 2010:548280; PMID:20625493; http://dx.doi.org/10.1155/2010/548280
13. Dahari H, Feinstone SM, Major ME. Metaanalysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010; 139:965-74; PMID:20621699; http://dx.doi.org/10.1053/j.gastro.2010.05.077
14. Kim Y, Vaughan K, Greenbaum J, Peters B, Law M, Sette A. A meta-analysis of the existing knowledge of immunoreactivity against hepatitis C virus (HCV). PLoS One 2012; 7:e38028; PMID:22675428; http://dx.doi.org/10.1371/journal.pone.0038028
15. Yahia M. Global health: a uniquely Egyptian epidemic. Nature 2011; 474:S12-3; PMID:21666728; http://dx.doi.org/10.1038/474S12a
16. De Groot AS. Epitope-based immunome-derived vaccines: A strategy for improved design and safety. Springer, NY; 2009.
17. iCubed: Institute for Immunology and Informatics. iVAX Tool Kit [Internet]. 2012. [Cited 2013 Nov 13]. Available from: http://www.immunome.org/ivax/ivax-tool-kit/.
18. Peters B, Sidney J, Bourne P, Bui HH, Buus S, Doh G, Fleri W, Kronenberg M, Kubo R, Lund O, et al. The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol 2005; 3:e91; PMID:15760272; http://dx.doi.org/10.1371/journal.pbio.0030091
19. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999; 50:201-12; PMID:10602880; http://dx.doi.org/10.1007/s002510050594
20. Petrovic D, Dempsey E, Doherty DG, Kelleher D, Long A. Hepatitis C virus - T-cell responses and viral escape mutations. Eur J Immunol 2012; 42:17-26; PMID:22125159; http://dx.doi.org/10.1002/eji.201141593
21. Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, VerBerkmoes NC, Sztein MB, Losikoff PT, Martin WD, et al. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother 2013; 9:1577-86; PMID:23584251; http://dx.doi.org/10.4161/hv.24615
22. Neumann-Haefelin C, Killinger T, Timm J, Southwood S, McKinney D, Blum HE, Thimme R. Absence of viral escape within a frequently recognized HLA-A26-restricted CD8+ T-cell epitope targeting the functionally constrained hepatitis C virus NS5A/5B cleavage site. J Gen Virol 2007; 88:1986-91; PMID:17554032; http://dx.doi.org/10.1099/vir.0.82826-0
23. Neumann-Haefelin C, Timm J, Spangenberg HC, Wischniowski N, Nazarova N, Kersting N, Roggendorf M, Allen TM, Blum HE, Thimme R. Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology 2008; 47:1824-36; PMID:18454507; http://dx.doi.org/10.1002/hep.22242
24. Wentworth PA, Sette A, Celis E, Sidney J, Southwood S, Crimi C, Stitely S, Keogh E, Wong NC, Livingston B, et al. Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. Int Immunol 1996; 8:651-9; PMID:8671652; http://dx.doi.org/10.1093/intimm/8.5.651
25. Mashiba T, Udaka K, Hirachi Y, Hiasa Y, Miyakawa T, Satta Y, Osoda T, Kataoka S, Kohara M, Onji M. Identification of CTL epitopes in hepatitis C virus by a genome-wide computational scanning and a rational design of peptide vaccine. Immunogenetics 2007; 59:197-209; PMID:17225159; http://dx.doi.org/10.1007/s00251-006-0185-3
26. Nakamoto Y, Kaneko S, Takizawa H, Kikumoto Y, Takano M, Himeda Y, Kobayashi K. Analysis of the CD8-positive T cell response in Japanese patients with chronic hepatitis C using HLA-A∗2402 peptide tetramers. J Med Virol 2003; 70:51-61; PMID:12629644; http://dx.doi.org/10.1002/jmv.10349
27. Kaji K, Nakamoto Y, Kaneko S. Analysis of hepatitis C virus-specific CD8+ T-cells with HLA-A∗24 tetramers during phlebotomy and interferon therapy for chronic hepatitis C. Oncol Rep 2007; 18:993-8; PMID:17786365
28. Gruener NH, Jung MC, Ulsenheimer A, Gerlach JT, Zachoval R, Diepolder HM, Baretton G, Schauer R, Pape GR, Schirren CA. Analysis of a successful HCV-specific CD8+ T cell response in patients with recurrent HCV-infection after orthotopic liver transplantation. Liver Transpl 2004; 10:1487-96; PMID:15558593; http://dx.doi.org/10.1002/lt.20300
29. Christie JM, Chapel H, Chapman RW, Rosenberg WM. Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. Hepatology 1999; 30:1037-44; PMID:10498657; http://dx.doi.org/10.1002/hep.510300403
30. Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR, Reiser M, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004; 127:924-36; PMID:15362047; http://dx.doi.org/10.1053/j.gastro.2004.06.015
31. Cucchiarini M, Kammer AR, Grabscheid B, Diepolder HM, Gerlach TJ, Grüner N, Santantonio T, Reichen J, Pape GR, Cerny A. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol 2000; 203:111-23; PMID:11006009; http://dx.doi.org/10.1006/cimm.2000.1683
32. Grüner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, Hoffmann R, Zachoval R, Santantonio T, Cucchiarini M, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000; 181:1528-36; PMID:10823750; http://dx.doi.org/10.1086/315450
33. Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, Reiser M, Kim AY, Lucas M, Klenerman P, et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 2002; 76:6104-13; PMID:12021343; http://dx.doi.org/10.1128/JVI.76.12.6104-6113.2002
34. Grey HM, Ruppert J, Vitiello A, Sidney J, Kast WM, Kubo RT, Sette A. Class I MHC-peptide interactions: structural requirements and functional implications. Cancer Surv 1995; 22:37-49; PMID:7536628
35. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993; 74:929-37; PMID:8104103; http://dx.doi.org/10.1016/0092-8674(93)90472-3
36. Bertoni R, Sette A, Sidney J, Guidotti LG, Shapiro M, Purcell R, Chisari FV. Human class I supertypes and CTL repertoires extend to chimpanzees. J Immunol 1998; 161:4447-55; PMID:9780224
37. Alexander J, Del Guercio MF, Fikes JD, Chesnut RW, Chisari FV, Chang KM, Appella E, Sette A. Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity. Hum Immunol 1998; 59:776-82; PMID:9831133; http://dx.doi.org/10.1016/S0198-8859(98)00080-9
38. Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, Chircu ML, Sidney J, Southwood S, Abrignani S, et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999; 162:6681-9; PMID:10352286
39. Sidney J, Southwood S, Mann DL, Fernandez-Vina MA, Newman MJ, Sette A. Majority of peptides binding HLA-A∗0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol 2001; 62:1200-16; PMID:11704282; http://dx.doi.org/10.1016/S0198-8859(01)00319-6
40. Himoudi N, Abraham JD, Fournillier A, Lone YC, Joubert A, Op De Beeck A, Freida D, Lemonnier F, Kieny MP, Inchauspé G. Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol 2002; 76:12735-46; PMID:12438599; http://dx.doi.org/10.1128/JVI.76.24.12735-12746.2002
41. Battegay M, Fikes J, Di Bisceglie AM, Wentworth PA, Sette A, Celis E, Ching WM, Grakoui A, Rice CM, Kurokohchi K, et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995; 69:2462-70; PMID:7884894
42. Ohno S, Moriya O, Yoshimoto T, Hayashi H, Akatsuka T, Matsui M. Immunogenic variation between multiple HLA-A∗0201-restricted, Hepatitis C Virus-derived epitopes for cytotoxic T lymphocytes. Viral Immunol 2006; 19:458-67; PMID:16987064; http://dx.doi.org/10.1089/vim.2006.19.458
43. Ishizuka J, Grebe K, Shenderov E, Peters B, Chen Q, Peng Y, Wang L, Dong T, Pasquetto V, Oseroff C, et al. Quantitating T cell cross-reactivity for unrelated peptide antigens. J Immunol 2009; 183:4337-45; PMID:19734234; http://dx.doi.org/10.4049/jimmunol.0901607
44. Anthony DD, Valdez H, Post AB, Carlson NL, Heeger PS, Lehmann PV. Comprehensive determinant mapping of the hepatitis C-specific CD8 cell repertoire reveals unpredicted immune hierarchy. Clin Immunol 2002; 103:264-76; PMID:12173301; http://dx.doi.org/10.1006/clim.2001.5193
45. Fitzmaurice K, Petrovic D, Ramamurthy N, Simmons R, Merani S, Gaudieri S, Sims S, Dempsey E, Freitas E, Lea S, et al. Molecular footprints reveal the impact of the protective HLA-A∗03 allele in hepatitis C virus infection. Gut 2011; 60:1563-71; PMID:21551190; http://dx.doi.org/10.1136/gut.2010.228403
46. Tsai SL, Sheen IS, Chien RN, Chu CM, Huang HC, Chuang YL, Lee TH, Liao SK, Lin CL, Kuo GC, et al. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci 2003; 10:120-35; PMID:12566993; http://dx.doi.org/10.1007/BF02256004
47. Tsai SL, Lee TH, Chien RN, Liao SK, Lin CL, Kuo GC, Liaw YF. A method to increase tetramer staining efficiency of CD8+ T cells with MHC-peptide complexes: therapeutic applications in monitoring cytotoxic T lymphocyte activity during hepatitis B and C treatment. J Immunol Methods 2004; 285:71-87; PMID:14871536; http://dx.doi.org/10.1016/j.jim.2003.11.005
48. Thammanichanond D, Moneer S, Yotnda P, Aitken C, Earnest-Silveira L, Jackson D, Hellard M, McCluskey J, Torresi J, Bharadwaj M. Fiber-modified recombinant adenoviral constructs encoding hepatitis C virus proteins induce potent HCV-specific T cell response. Clin Immunol 2008; 128:329-39; PMID:18524682; http://dx.doi.org/10.1016/j.clim.2008.04.002
49. Guo Z, Zhang H, Rao H, Jiang D, Cong X, Feng B, Wang J, Wei L, Chen H. DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response. PLoS One 2012; 7:e38390; PMID:22701633; http://dx.doi.org/10.1371/journal.pone.0038390
50. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol 2008; 9:1; PMID:18211710; http://dx.doi.org/10.1186/1471-2172-9-1
51. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998; 160:3363-73; PMID:9531296
52. Diepolder HM, Gerlach JT, Zachoval R, Hoffmann RM, Jung MC, Wierenga EA, Scholz S, Santantonio T, Houghton M, Southwood S, et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997; 71:6011-9; PMID:9223492
53. Pape GR, Gerlach TJ, Diepolder HM, Grüner N, Jung M, Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. J Viral Hepat 1999; 6(Suppl 1):36-40; PMID:10760033; http://dx.doi.org/10.1046/j.1365-2893.1999.00006.x
54. Shoukry NH, Sidney J, Sette A, Walker CM. Conserved hierarchy of helper T cell responses in a chimpanzee during primary and secondary hepatitis C virus infections. J Immunol 2004; 172:483-92; PMID:14688358; http://dx.doi.org/10.4049/jimmunol.172.1.483
55. Day CL, Seth NP, Lucas M, Appel H, Gauthier L, Lauer GM, Robbins GK, Szczepiorkowski ZM, Casson DR, Chung RT, et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest 2003; 112:831-42; PMID:12975468; http://dx.doi.org/10.1172/JCI200318509
56. Castelli FA, Leleu M, Pouvelle-Moratille S, Farci S, Zarour HM, Andrieu M, Auriault C, Ménez A, Georges B, Maillere B. Differential capacity of T cell priming in naive donors of promiscuous CD4+ T cell epitopes of HCV NS3 and Core proteins. Eur J Immunol 2007; 37:1513-23; PMID:17492804; http://dx.doi.org/10.1002/eji.200636783
57. Lamonaca V, Missale G, Urbani S, Pilli M, Boni C, Mori C, Sette A, Massari M, Southwood S, Bertoni R, et al. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology 1999; 30:1088-98; PMID:10498664; http://dx.doi.org/10.1002/hep.510300435
58. Harcourt GC, Lucas M, Sheridan I, Barnes E, Phillips R, Klenerman P. Longitudinal mapping of protective CD4+ T cell responses against HCV: analysis of fluctuating dominant and subdominant HLA-DR11 restricted epitopes. J Viral Hepat 2004; 11:324-31; PMID:15230855; http://dx.doi.org/10.1111/j.1365-2893.2004.00516.x
59. Ebinuma H, Nakamoto N, Li Y, Price DA, Gostick E, Levine BL, Tobias J, Kwok WW, Chang KM. Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection. J Virol 2008; 82:5043-53; PMID:18337568; http://dx.doi.org/10.1128/JVI.01548-07
60. Eckels DD, Bian T, Gill JC, Sønderstrup G. Epitopes of the NS3 protein of hepatitis C virus: recognition in HLA-DR4 transgenic mice. Immunol Cell Biol 2002; 80:106-12; PMID:11869368; http://dx.doi.org/10.1046/j.1440-1711.2002.01053.x
61. Schulze Zur Wiesch J, Sidney J, Walker B, Sette A. Direct Submission. 2006.
62. Schulze zur Wiesch J, Lauer GM, Day CL, Kim AY, Ouchi K, Duncan JE, Wurcel AG, Timm J, Jones AM, Mothe B, et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 2005; 175:3603-13; PMID:16148104; http://dx.doi.org/10.4049/jimmunol.175.6.3603
63. Wang Y, Keck ZY, Foung SK. Neutralizing antibody response to hepatitis C virus. Viruses 2011; 3:2127-45; PMID:22163337; http://dx.doi.org/10.3390/v3112127
64. He L, De Groot AS, Gutierrez AH, Martin WD, Moise L, Bailey-Kellogg C. Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage. BMC Bioinformatics 2014; 15:S1
65. De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol 2009; 131:189-201; PMID:19269256; http://dx.doi.org/10.1016/j.clim.2009.01.009
66. Duvvuri VR, Duvvuri B, Alice C, Wu GE, Gubbay JB, Wu J. Preexisting CD4+ T-cell immunity in human population to avian influenza H7N9 virus: whole proteome-wide immunoinformatics analyses. PLoS One 2014; 9:e91273; PMID:24609014; http://dx.doi.org/10.1371/journal.pone.0091273
67. Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother 2014; 15:121-30; PMID:24289735; http://dx.doi.org/10.1517/14656566.2014.857656
68. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics 2005; 21:379-84; PMID:15377502; http://dx.doi.org/10.1093/bioinformatics/bth485